Lithium Concentrations After Initiation or Discontinuation of SGLT2 Inhibitors in Psychiatric Inpatients

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular and renal risk, but coprescription with lithium raises concern because lithium elimination is linked to renal sodium handling. Prescribing information recommends lithium monitoring after SGLT2i initiation or dose changes, although clinical evidence remains limited, particularly after discontinuation. We describe lithium concentrations and clinical evolution after SGLT2i initiation or discontinuation in lithium-treated psychiatric inpatients. METHODS: We conducted a retrospective case series at a psychiatric hospital. Pharmacy records identified patients who received lithium and an SGLT2i between January 1, 2014 and March 31, 2026. Patients were included if the SGLT2i was initiated or discontinued while lithium was continued and ≥1 lithium concentration was available before and after modification. Clinical pharmacists reviewed records for lithium dose and concentrations, SGLT2i exposure, renal function, interacting medications, acute illness, hydration status, and adverse events. RESULTS: Six cases were identified: 3 initiations and 3 discontinuations. Lithium concentrations showed no consistent directional change. After initiation, concentrations remained stable or changed minimally in 2 cases and increased slightly in one. After discontinuation, lithium remained stable in an older patient with chronic kidney disease, increased slightly in 1 case confounded by lithium dose escalation, and increased from 0.6 to 0.8 mmol/l in 1 case complicated by pneumonia, diarrhea, and dehydration. No case required urgent lithium discontinuation, toxicity treatment, or prolonged hospitalization attributed to lithium. CONCLUSIONS: SGLT2i initiation or discontinuation was not associated with consistent or clinically concerning lithium changes. These observations suggest coprescription may be manageable with individualized monitoring when clinically indicated.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Psychopharmacology
Published
2026-10-29
DOI
https://doi.org/10.1097/jcp.0000000000002281
Primary Topic
Bipolar Disorder and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lithium Concentrations After Initiation or Discontinuation of SGLT2 Inhibitors in Psychiatric Inpatients

Olivier Corbeil, Pierre Duranleau-Gagnon, Marie‐France Demers, Laurent Béchard et al.
4 links
Journal of Clinical Psychopharmacology
Bipolar Disorder and Treatment
article

Lithium Concentrations After Initiation or Discontinuation of SGLT2 Inhibitors in Psychiatric Inpatients

Olivier Corbeil, Pierre Duranleau-Gagnon, Marie‐France Demers, Laurent Béchard, Katryn Langlois-Parisé
article en

Abstract

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular and renal risk, but coprescription with lithium raises concern because lithium elimination is linked to renal sodium handling. Prescribing information recommends lithium monitoring after SGLT2i initiation or dose changes, although clinical evidence remains limited, particularly after discontinuation. We describe lithium concentrations and clinical evolution after SGLT2i initiation or discontinuation in lithium-treated psychiatric inpatients. METHODS: We conducted a retrospective case series at a psychiatric hospital. Pharmacy records identified patients who received lithium and an SGLT2i between January 1, 2014 and March 31, 2026. Patients were included if the SGLT2i was initiated or discontinued while lithium was continued and ≥1 lithium concentration was available before and after modification. Clinical pharmacists reviewed records for lithium dose and concentrations, SGLT2i exposure, renal function, interacting medications, acute illness, hydration status, and adverse events. RESULTS: Six cases were identified: 3 initiations and 3 discontinuations. Lithium concentrations showed no consistent directional change. After initiation, concentrations remained stable or changed minimally in 2 cases and increased slightly in one. After discontinuation, lithium remained stable in an older patient with chronic kidney disease, increased slightly in 1 case confounded by lithium dose escalation, and increased from 0.6 to 0.8 mmol/l in 1 case complicated by pneumonia, diarrhea, and dehydration. No case required urgent lithium discontinuation, toxicity treatment, or prolonged hospitalization attributed to lithium. CONCLUSIONS: SGLT2i initiation or discontinuation was not associated with consistent or clinically concerning lithium changes. These observations suggest coprescription may be manageable with individualized monitoring when clinically indicated.

Journal of Clinical Psychopharmacology
University of Ottawa (CA), Institut Universitaire en Santé Mentale de Québec (CA), Université Laval (CA), VITAM - Centre de recherche en santé durable (CA), Centre de recherche CERVO (CA), Ottawa University (US)
Good health and well-being
Openalex Percentile: Top 12%
Bipolar Disorder and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon